[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@jy201506 just a random dude

just a random dude posts on X about $iova, $legn, $482m, $12b the most. They currently have XXX followers and X posts still getting attention that total X engagements in the last XX hours.

Engagements: undefined #

• X Week XXXXX +41%
• X Month XXXXX -XX%

Mentions: undefined #

• X Week X -XX%
• X Month XX -XX%

Followers: XXX #

• X Week XXX +2.70%
• X Month XXX +17%

CreatorRank: undefined #

Social Influence

Social topic influence $iova 50%, $legn 25%, $482m 25%, $12b 25%, $850m 25%, $350m 25%, if you XX%

Top accounts mentioned or mentioned by @semodough @oldgoldhawkeye

Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA)

Top Social Posts

Top posts by engagements in the last XX hours

"Yescarta and Carvykti are examples of high-margin blockbuster autologous cell therapies. Legend Biotech $LEGN is an example of how a standalone autologous cell therapy company can be profitable. $IOVA will be profitable in 2028. Details see"
X Link 2025-11-15T19:01Z XXX followers, 1937 engagements

"i model much higher operating expenses than Truist's $482M number yet see $IOVA become profitable in 2028 much earlier than 2034 by Truist. My key assumptions are 1) 2L NSCLC launch in 2028 and 2) GM reach XX% in 2028. this would lead to a combined product rev of $1.2B operating expense of $850M operation income of $350M in 2028. I bet Truist gave zero credit in 2L NSCLC. If you believe $IOVA's story in 2L NSCLC then it would be a good buy here. Otherwise you should sell"
X Link 2025-12-05T15:18Z XXX followers, 1857 engagements